Cargando…
Time-dependent endpoints as predictors of overall survival in multiple myeloma
BACKGROUND: Supporting health care sector decisions using time-dependent endpoints (TDEs) such as time to progression (TTP), progression-free survival (PFS), and event-free survival (EFS) remains controversial. This study estimated the quantitative relationship between median TDE and median overall...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607860/ https://www.ncbi.nlm.nih.gov/pubmed/23497363 http://dx.doi.org/10.1186/1471-2407-13-122 |
_version_ | 1782264155781201920 |
---|---|
author | Félix, Jorge Aragão, Filipa Almeida, João M Calado, Frederico JM Ferreira, Diana Parreira, António BS Rodrigues, Ricardo Rijo, João FR |
author_facet | Félix, Jorge Aragão, Filipa Almeida, João M Calado, Frederico JM Ferreira, Diana Parreira, António BS Rodrigues, Ricardo Rijo, João FR |
author_sort | Félix, Jorge |
collection | PubMed |
description | BACKGROUND: Supporting health care sector decisions using time-dependent endpoints (TDEs) such as time to progression (TTP), progression-free survival (PFS), and event-free survival (EFS) remains controversial. This study estimated the quantitative relationship between median TDE and median overall survival (OS) in multiple myeloma (MM) patients. METHODS: Studies (excluding allogeneic transplantation) published from 1970 to 2011 were systematically searched (PubMed). The nonparametric Spearman’s rank correlation coefficient measured the association between median TDE and OS. The quantitative relationship between TDEs and OS was estimated with a two-step approach to a simultaneous Tobit model. RESULTS: We identified 153 studies: 230 treatment arms, 22,696 patients and mean study duration of 3.8 years. Mean of median TDEs was 22.5 months and median OS was 39.1 months. Correlation coefficients of median TTP, PFS, and EFS with median OS were 0.51 (P = 0.003), 0.75 (P < 0.0001), and 0.84 (P < 0.0001), respectively. We estimate a 2.5 month (95% confidence interval, 1.7–3.2) increase in median OS for each additional month reported for median TDEs. There was no evidence that this relationship differed by type of surrogate. CONCLUSION: TDEs predict OS in MM patients; this relationship may be valuable in clinical trial design, drug comparisons, and economic evaluation. |
format | Online Article Text |
id | pubmed-3607860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36078602013-03-27 Time-dependent endpoints as predictors of overall survival in multiple myeloma Félix, Jorge Aragão, Filipa Almeida, João M Calado, Frederico JM Ferreira, Diana Parreira, António BS Rodrigues, Ricardo Rijo, João FR BMC Cancer Research Article BACKGROUND: Supporting health care sector decisions using time-dependent endpoints (TDEs) such as time to progression (TTP), progression-free survival (PFS), and event-free survival (EFS) remains controversial. This study estimated the quantitative relationship between median TDE and median overall survival (OS) in multiple myeloma (MM) patients. METHODS: Studies (excluding allogeneic transplantation) published from 1970 to 2011 were systematically searched (PubMed). The nonparametric Spearman’s rank correlation coefficient measured the association between median TDE and OS. The quantitative relationship between TDEs and OS was estimated with a two-step approach to a simultaneous Tobit model. RESULTS: We identified 153 studies: 230 treatment arms, 22,696 patients and mean study duration of 3.8 years. Mean of median TDEs was 22.5 months and median OS was 39.1 months. Correlation coefficients of median TTP, PFS, and EFS with median OS were 0.51 (P = 0.003), 0.75 (P < 0.0001), and 0.84 (P < 0.0001), respectively. We estimate a 2.5 month (95% confidence interval, 1.7–3.2) increase in median OS for each additional month reported for median TDEs. There was no evidence that this relationship differed by type of surrogate. CONCLUSION: TDEs predict OS in MM patients; this relationship may be valuable in clinical trial design, drug comparisons, and economic evaluation. BioMed Central 2013-03-16 /pmc/articles/PMC3607860/ /pubmed/23497363 http://dx.doi.org/10.1186/1471-2407-13-122 Text en Copyright ©2013 Félix et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Félix, Jorge Aragão, Filipa Almeida, João M Calado, Frederico JM Ferreira, Diana Parreira, António BS Rodrigues, Ricardo Rijo, João FR Time-dependent endpoints as predictors of overall survival in multiple myeloma |
title | Time-dependent endpoints as predictors of overall survival in multiple myeloma |
title_full | Time-dependent endpoints as predictors of overall survival in multiple myeloma |
title_fullStr | Time-dependent endpoints as predictors of overall survival in multiple myeloma |
title_full_unstemmed | Time-dependent endpoints as predictors of overall survival in multiple myeloma |
title_short | Time-dependent endpoints as predictors of overall survival in multiple myeloma |
title_sort | time-dependent endpoints as predictors of overall survival in multiple myeloma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607860/ https://www.ncbi.nlm.nih.gov/pubmed/23497363 http://dx.doi.org/10.1186/1471-2407-13-122 |
work_keys_str_mv | AT felixjorge timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma AT aragaofilipa timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma AT almeidajoaom timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma AT caladofredericojm timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma AT ferreiradiana timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma AT parreiraantoniobs timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma AT rodriguesricardo timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma AT rijojoaofr timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma |